Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer?
Glucagon-like peptide-1 (GLP-1) receptor agonists, with few reported side effects, are a kind of very promising anti-diabetes drugs. They are thus being paid high hopes on by both doctors and patients. GLP-1 receptor agonists, however, have not been used in clinic for a long time. Some unknown potential adverse effects may exist. Because GLP-1 receptor agonists enhance β cells proliferation in pancreas via influencing Wnt/β-catenin pathway, a pathway which is associated with tumorigenesis in colon, we then assume that GLP-1 receptor agonists may increase the risk for colorectal cancer.